Safety and Efficacy of AGN-INM176 in Prostate Patients With Rising PSA

This Phase I/II open-label trial aims to evaluate the safety and efficacy of the herbal supplement INM176 in patients with a history of prostate cancer or low-risk disease under active surveillance. The study will determine the recommended Phase II dose (RP2D) and assess the efficacy of INM176 in stabilizing or decreasing plasma PSA levels in post-radical prostatectomy (RP) and post-radiation therapy (RT) patients with rising PSA levels.

Trial Details

NCT ID
NCT06600698
Phase
PHASE1 / PHASE2
Sponsor
Milton S. Hershey Medical Center
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • INM176
Locations (sample)
  • Hershey, Pennsylvania, United States|40.28592,-76.65025

Key Eligibility Criteria

  • Phase I Inclusion Criteria
  • Willingness and ability to give informed consent.
  • Agree to comply with all study procedures and attend all study visits.
  • Male aged \>=40 years.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →